Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M4YC
|
|||
| Former ID |
DAP000504
|
|||
| Drug Name |
Disopyramide
|
|||
| Synonyms |
Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ventricular arrhythmias [ICD-11: BC71; ICD-10: I49, I49.8; ICD-9: 427.1] | Approved | [1], [2] | |
| Urinary incontinence [ICD-11: MF50.2; ICD-9: 788.3] | Withdrawn from market | [1], [3] | ||
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Company |
Gd Searle Llc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H29N3O
|
|||
| Canonical SMILES |
CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
|
|||
| InChI |
1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
|
|||
| InChIKey |
UVTNFZQICZKOEM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 3737-09-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9179, 7343341, 7847369, 7979107, 8151982, 10321641, 10520689, 11335664, 11360903, 11363902, 11366464, 11369026, 11371248, 11374266, 11377188, 11461875, 11466294, 11467414, 11484981, 11486067, 11488849, 11490220, 11492339, 11494822, 14777930, 17404965, 24278384, 29222256, 46508226, 47440202, 47736425, 47810710, 47959691, 47959692, 47959693, 48035065, 48110414, 48184952, 49698859, 50068860, 50106174, 50106175, 50106176, 50899557, 53777508, 53786857, 56394974, 57321616, 85085689, 85148360
|
|||
| ChEBI ID |
CHEBI:4657
|
|||
| ADReCS Drug ID | BADD_D00693 ; BADD_D00694 | |||
| SuperDrug ATC ID |
C01BA03
|
|||
| SuperDrug CAS ID |
cas=003737095
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target Info | Blocker | [4] |
| KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7167). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070101. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.